An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
Monoclonal antibodies targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 monoclonal antibodies in the clinic, the experimental relationshi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis,
2022-08-09T14:40:28Z.
|
| Subjects: | |
| Online Access: | Get fulltext |